Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in
Pharmacopedia is being built in public. Pages may be incomplete.About this site

Choose a table:


Medicines > generic : 25I-NBOMe or 2C-B or Rivaroxaban

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
None (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Xarelto (1)
classes:
2C-x series (1) · Classic Psychedelic (1) · Phenethylamine (2) · Psychedelic (1) · Research material (1) · [[:Category:Anticoagulants|Anticoagulant]] (1) · [[:Category:Direct_factor_Xa_inhibitors|Direct factor Xa inhibitor]] (1) · [[:Category:DOACs|Direct oral anticoagulant (DOAC)]] (1)
mechanism:
5-HT2A partial agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · '"`UNIQ--vote-0000050D-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-0000050E-QINU`"'. (1)
uses:
None (2) · '"`UNIQ--vote-0000050F-QINU`"', '"`UNIQ--vote-00000510-QINU`"', '"`UNIQ--vote-00000511-QINU`"', '"`UNIQ--vote-00000512-QINU`"' (1)
starting dose:
None (2) · NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin (1)
preparations:
None (2) · 2.5, 10, 15, 20 mg tablets (1)
fda max:
None (2) · 30 mg/d (acute VTE first 21 days as 15 mg BID); otherwise 20 mg/d (1)
routes:
None (1) · insufflated (1) · Oral (2) · PR (1)
onset:
None (1) · 45-75 min (oral) (1) · Peak anticoagulant effect 2-4 hours (1)
duration:
None (1) · 24 hours (1) · 4-8 h (1)
halflife:
None (1) · 5-9 hours (elderly: 11-13 hours)'"`UNIQ--ref-00000513-QINU`"' (1) · Not well characterized (1)
bioavailability:
None (1) · Not well characterized (1) · ~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"' (1)
pregnancy:
None (1) · Avoid in pregnancy; switch to LMWH. Crosses placenta; warfarin-class concerns about fetal hemorrhage and teratogenicity make heparins the preferred class.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)
legal:
None (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 3 results in range #1 to #3.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"